FDA Approves CALQUENCE — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's CALQUENCE (acalabrutinib) AstraZeneca Pharmaceuticals LP received FDA approval for CALQUENCE (acalabrutinib), an oral Bruton's tyrosine kinase inhibitor, strengthening the company's oncology portfolio in the competitive blood cancer market. The approval expands AstraZeneca's BTK inhibitor offerings and positions the company to capture additional market share in hematologic malignancies where BTK inhibitors represent a significant revenue opportunity.